Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNAC: Tranilast plus neoadjuvant 5-FU/cisplatin in esophageal squamous cell carcinoma
jRCTs051190076Phase 2Suspended
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tranilast in Esophageal Squamous Cell Carcinoma (ESCC). Primary endpoint: Pathological therapeutic effect. Started Nov 2019; status: suspended.
02
Drugs
tranilast
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on jRCTs051190076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051190076.